Equity Overview
Price & Market Data
Price: $96.29
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $19,082,117,120
Daily Volume: 0
Performance Metrics
1 Week: 3.86%
1 Month: -2.14%
3 Months: 22.93%
6 Months: 106.1%
1 Year: 206.7%
YTD: 20.89%
Company Details
Employees: 883
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.